Clinical Trials on Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Total 3667 results

ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects (ING112276)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Germany, Italy, Russian Federation
ViiV Healthcare
GlaxoSmithKline

Terminated

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection (SONNET)

Infection, Human Immunodeficiency Virus

United States, Canada, Italy, Belgium, Romania
ViiV Healthcare
GlaxoSmithKline

Completed

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Infection, Human Immunodeficiency Virus I

United States, Spain, Canada, Russian Federation, Romania, Belgium, South Africa
ViiV Healthcare
GlaxoSmithKline

Completed

Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients

Infection, Human Immunodeficiency Virus
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

Hepatitis C | HIV-1 Infection

United States
Janssen Inc.

Completed

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients (POISE)

Human Immunodeficiency Virus (HIV)

Canada
Peking Union Medical College Hospital
Gilead Sciences

Active, not recruiting

Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

HIV-1-infection

China
Gilead Sciences

Completed

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

HIV Infections | Acquired Immunodeficiency Syndrome | HIV-1

United States, Canada
VA Eastern Colorado Health Care System
Public Health Grant Program, Veterans Health Administration Office of Public...

Completed

Veterans Living With HIV/AIDS: A Pilot Study Examining Risk Factors Associated With Self-Directed Violence

Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) | Self-Directed Violence

United States
Janssen R&D Ireland

Completed

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Hepatitis C Virus Genotype-1

United States, France, United Kingdom, Germany, Spain, Portugal, Canada, Puerto Rico
Dartmouth-Hitchcock Medical Center

Completed

HSV Oral Reactivation in Children

HIV | HSV-1

Tanzania
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Spain, United Kingdom, Canada, Thailand, Italy, Portugal, Russian Federation, Mexico, Argentina, South Africa, Puerto Rico
Abbott

Completed

Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

Human Immunodeficiency Virus-Infection

Germany
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Centre for the...

Recruiting

Simplifying Treatment and Monitoring for HIV (STREAM HIV)

HIV/AIDS | HIV-1-infection

South Africa
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

HIV Infections | Infection, Human Immunodeficiency Virus

Taiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status

Infection, Human Immunodeficiency Virus | Fracture
International Maternal Pediatric Adolescent AIDS...
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth

Influenza | HIV-1 Infection | Flu | H1N1

United States, Puerto Rico
Eva Bonfill

Recruiting

Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection (DASAHIVCURE)

Recent HIV-1 Infection

Spain
Gilead Sciences

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

HIV-1-infection

United States, Spain, France, Taiwan, Japan, Thailand, Dominican Republic, Germany, Canada, Italy, South Africa
Shanghai Public Health Clinical Center
Yunnan AIDS Care Center; Xixi Hospital of Hangzhou

Active, not recruiting

Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

HIV-1-infection

China
ANRS, Emerging Infectious Diseases
MSD France

Not yet recruiting

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (ELDORADO)

HIV-1-infection

Brazil, Cambodia, Cameroon, Côte D'Ivoire, France, Mozambique
ST Pharm Co., Ltd.

Recruiting

A Clinical Trial of STP0404 in Treatment-Naïve Adults With HIV-1 Infection

HIV-1-infection

United States
Erasmus Medical Center

Recruiting

Self-testing for HCV Re-infection in MSM (SELFIE)

HIV-1-infection | Hepatitis C Recurrent

Netherlands
University of Hawaii
Tobira Therapeutics, Inc.

Completed

Effect of Cenicriviroc on HIV Neurocognitive Impairment

AIDS Dementia Complex | Human Immunodeficiency Virus | HIV-1-Associated Cognitive Motor Complex

United States
Johnson & Johnson Pte Ltd

Terminated

A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (RISE)

Human Immunodeficiency Virus Infections

India
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences; Janssen-Cilag Ltd.

Completed

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

HIV-1 Infections

France
GlaxoSmithKline

Completed

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

HIV Infections | Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline
University Ghent

Completed

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

HIV Infections | Infection, Human Immunodeficiency Virus

Belgium
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Expanded Access Study (DEAP)

HIV Infections | Infection, Human Immunodeficiency Virus

France, Germany, United States, Canada, Belgium, Austria, Brazil, Italy, Poland
ViiV Healthcare

Completed

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

HIV Infections | Infection, Human Immunodeficiency Virus

United States
International AIDS Vaccine Initiative
Targeted Genetics Corporation

Completed

Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid (TGC14F)

HIV Infections | Human Immunodeficiency Virus Infections

Uganda, South Africa, Zambia
ViiV Healthcare
GlaxoSmithKline

Completed

Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection

HIV Infections | Infection, Human Immunodeficiency Virus

Mexico, Peru, Thailand, South Africa, Russian Federation, Argentina, Brazil
University Hospital, Montpellier
Institute of Human Genetics, France

Completed

Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy (RALNOVO)

HIV-1 Infection

France
Hospitales Universitarios Virgen del Rocío

Completed

Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (RAET)

HIV Infections | HIV-1 Infection

Spain
University of Pennsylvania
National Institute of Mental Health (NIMH)

Completed

Reality Check: An HIV Risk Reduction Serial Drama (RC)

Sexually Transmitted Diseases | HIV (Human Immunodeficiency Virus)

United States
Georgetown University
GlaxoSmithKline

Completed

A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT (SUPPoRT)

Human Immunodeficiency Virus Infections

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Retrovirus Epidemiology Donor Study I (REDS I)

HIV Infections | Acquired Immunodeficiency Syndrome | Retroviridae Infections | Blood Transfusion | HIV-1 | Blood Donors | HIV-2 | HTLV-I | HTLV-II
AbbVie

Completed

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

Human Immunodeficiency Virus (HIV)

United States, Puerto Rico
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults (SAILING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Netherlands, Spain, Taiwan, Australia, Belgium, Russian Federation, Canada, United Kingdom, Mexico, Italy, South Africa, Romania, Argentina, Hungary, Poland, Chile, Greece, Brazil
ViiV Healthcare
GlaxoSmithKline

Completed

GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers

HIV Infections | Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

HIV Infections | Infection, Human Immunodeficiency Virus

United States
Shenzhen Immuno Cure Biomedical Company Limited
Shenzhen Third People's Hospital

Active, not recruiting

ICVAX as a HIV Therapeutic DNA Vaccine

Human Immunodeficiency Virus | Human Immunodeficiency Virus I Infection

China
ViiV Healthcare
GlaxoSmithKline

Completed

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers (ING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Terminated

A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)

Infection, Human Immunodeficiency Virus I
Vancouver Infectious Diseases Centre

Unknown

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed

Drug Use | Human Immunodeficiency Virus I Infection

Canada
Université Catholique de Louvain
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Completed

Optimization of Darunavir Therapy and Dosage Recommendations

Human Immunodeficiency Virus I Infection

Belgium

Clinical Trials on Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations